Sangamo plunges 38% after Pfizer ends agreement on hemophilia A gene therapy
by
Contributor since / Followers
Contributor since / Followers
3 days ago
pictafolio
- Sangamo Therapeutics (NASDAQ:SGMO) is down ~38% in after-hours trading Monday after announcing that Pfizer (NYSE:PFE) is returning the development and commercialization rights to hemophilia A gene therapy candidate giroctocogene fitelparvovec.
- Sangamo said Pfizer has decided not to pursue commercialization of